O34: WHO SHOULD BE FOLLOWING UP IN PATIENTS WITH PROSTATE CANCER USING PSAS?

Abstract Introdution Prostate cancer patients are usually followed up using serial PSA testing. NICE provides guidelines for follow however whether this should be in primary care or secondary is ambiguous. Consequently, there a concern that PSAs being missed. The aim of study was to understand were Method A retrospective carried out at Whitehill General Practice. Patients identified codes prostate through Egton Medical Information Systems (EMIS) software. Data with between 2015-2019 collected manually from documentation. Chi-squared statistical testing used. Result 47 had repeat PSAs. 45% solely by whilst 40% directed specialists. 7 excluded further analysis. 35% missed PSAs, which 18% no reason documented. Furthermore, 19% up. difference versus those regularly specialists not significant (chi-squared 0.0177, p>0.05). Conclusion because lack recall system. An ‘out hospital’ system local administrative hub would allow standardisation. Involving their also considered. By placing the responsibility centrally rather than individual clinicians multiple fail safes reduce ups. Take-home message needs